
Incyte Corporation
INCYAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 30, 2026 | UBS | $152.00(+30%) | $116.80 | StreetInsider | |
| Oct 30, 2026 | Oppenheimer | Jay Olson | $144.00(+23%) | $116.80 | StreetInsider |
| Oct 27, 2026 | Oppenheimer | $152.00(+34%) | $113.31 | StreetInsider | |
| Oct 16, 2026 | Raymond James | $152.00(+34%) | $113.27 | StreetInsider | |
| Oct 14, 2026 | Truist Financial | Srikripa Devarakonda | $115.00(+3%) | $111.44 | TheFly |
| Oct 8, 2026 | RBC Capital | $114.00(+2%) | $111.78 | TheFly | |
| Oct 5, 2026 | UBS | Ashwani Verma | $127.00(+12%) | $113.03 | StreetInsider |
| Oct 5, 2026 | Stifel Nicolaus | Stephen Willey | $157.00(+36%) | $115.30 | StreetInsider |
| Sep 28, 2026 | H.C. Wainwright | Mitchell Kapoor | $152.00(+23%) | $123.89 | StreetInsider |
| Aug 20, 2026 | Canaccord Genuity | $152.00(+18%) | $128.47 | TheFly | |
| Aug 17, 2026 | Piper Sandler | Allison Bratzel | $130.00(+8%) | $120.16 | TheFly |
| Aug 13, 2026 | Bernstein | $104.00(-14%) | $120.77 | TheFly | |
| Aug 3, 2026 | Leerink Partners | Andrew Berens | $155.00(+30%) | $119.52 | TheFly |
| Jul 29, 2026 | RBC Capital | Brian Abrahams | $109.00(-14%) | $126.69 | TheFly |
| Jul 29, 2026 | BMO Capital | $130.00(+1%) | $128.83 | TheFly | |
| Jul 29, 2026 | Guggenheim | Whitney Ljem | $150.00(+15%) | $129.93 | StreetInsider |
| Jul 29, 2026 | Morgan Stanley | $119.00(-8%) | $129.93 | TheFly | |
| Jul 29, 2026 | H.C. Wainwright | $150.00(+15%) | $129.93 | TheFly | |
| Jul 29, 2026 | Barclays | $139.00(+7%) | $129.93 | TheFly | |
| Jul 28, 2026 | Stifel Nicolaus | Stephen Willey | $145.00(+11%) | $130.08 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Leerink Partners | maintain | Outperform | Nov 5, 2026 |
| Bernstein | maintain | Market Perform | Nov 2, 2026 |
| RBC Capital | maintain | Sector Perform | Oct 30, 2026 |
| Wells Fargo | maintain | Equal Weight | Oct 30, 2026 |
| Oppenheimer | upgrade | Perform →Outperform | Oct 30, 2026 |
| Evercore ISI Group | maintain | In Line | Oct 30, 2026 |
| Barclays | maintain | Overweight | Oct 30, 2026 |
| TD Cowen | maintain | Buy | Oct 21, 2026 |
| Truist Securities | maintain | Hold | Oct 14, 2026 |
| HC Wainwright & Co. | maintain | Buy | Oct 13, 2026 |
| RBC Capital | maintain | Sector Perform | Oct 8, 2026 |
| Stifel | maintain | Buy | Oct 5, 2026 |
| Wells Fargo | maintain | Equal Weight | Oct 1, 2026 |
| HC Wainwright & Co. | maintain | Buy | Sep 28, 2026 |
| JP Morgan | maintain | Neutral | Sep 28, 2026 |
| RBC Capital | maintain | Sector Perform | Sep 22, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 20, 2026 |
| Piper Sandler | maintain | Overweight | Aug 17, 2026 |
| Mizuho | maintain | Outperform | Aug 4, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 3, 2026 |
| Leerink Partners | maintain | Outperform | Aug 3, 2026 |
| Barclays | maintain | Overweight | Jul 29, 2026 |
| BMO Capital | maintain | Market Perform | Jul 29, 2026 |
| Guggenheim | maintain | Buy | Jul 29, 2026 |
| RBC Capital | maintain | Sector Perform | Jul 29, 2026 |
Earnings History
Next report: Feb 9, 2027 · EPS est. $1.90| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 29, 2026 | $-3.60 | $-3.93 | $1.56B | $1.46B |
| Jul 28, 2026 | $3.09 | $2.15 | $1.67B | $1.50B |
| Apr 28, 2026 | $1.81 | $1.34 | $1.27B | $1.22B |
| Feb 10, 2026 | $1.80 | $1.90 | $1.51B | $1.35B |
| Oct 28, 2025 | $2.26 | $1.66 | $1.37B | $1.35B |
| Jul 29, 2025 | $1.57 | $1.39 | $1.22B | $1.26B |
| Apr 29, 2025 | $1.16 | $1.01 | $1.05B | $1.15B |
| Feb 10, 2025 | $1.43 | $1.57 | $1.18B | $1.00B |
News
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte is proud to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute have been selected as the recipients of the 2026 Incyte Ingenuity Awards in GVHD™. This annual award program recognizes and supports innovative projects that address the specific needs of individuals impacted by graft-versus-host disease (GVHD), including patients, caregivers and healthcare providers. “It is our honor to reco.
Compass Financial Management LLC bought a new position in shares of Incyte Corporation (NASDAQ: INCY) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 19,594 shares of the biopharmaceutical company's stock, valued at approximately $2,378,000. Other hedge
Aware Super Pty Ltd as trustee of Aware Super lowered its position in Incyte Corporation (NASDAQ: INCY) by 4.5% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 293,117 shares of the biopharmaceutical company's stock after selling 13,693 shares during the
Pre-Market Stock Futures: Futures are trading lower this Friday, with the Nasdaq down almost 2.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
I upgraded Incyte to Hold, with a fair value of $112.19 per share, now just 4% below the market price. ESMO Phase 1 data for KRAS G12D and TGFβR2×PD-1 support higher approval probabilities. Q3 net sales rose 14% year-over-year; Opzelura and hematology/oncology guidance increased, while Jakafi guidance remains unchanged.
Incyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.
Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript
Incyte NASDAQ: INCY reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in Jakafi sales. The company also raised its full-year sales outlook for OPZELURA, hematology and oncology products, and total net sales while outlining progress across several late-stage pipeline programs.
Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Incyte (INCY) came out with a quarterly loss of $3.6 per share versus the Zacks Consensus Estimate of a loss of $3.99. This compares to earnings of $2.26 per share a year ago.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates.
Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript
Incyte NASDAQ: INCY presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “'890,” and INCB161734, a KRAS G12D-targeted small molecule known as “'734.”
INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO26--Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026.
[url="]Genmab A/S[/url] (Nasdaq: GMAB) and [url="]Incyte[/url] (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab's
COPENHAGEN, Denmark & WILMINGTON, Del.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab's investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte's investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a fi.
WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)---- $INCY--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer.
Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial collaboration to evaluate INCB161734, Incyte's investigational, potent and se